Interleukin‐33 (IL‐33), a cytokine secreted by endothelial and epithelial cells to activate NF‐κB and MAPK signalling, may also hold therapeutic interest for the reprogramming of endothelial cells and normalization of tumour vasculature in CRC. This evidence concerns the gene IL33 and colorectal carcinoma.